Jun 28 |
AbbVie completes acquisition of Celsius Therapeutics for $250m
|
Jun 28 |
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
|
Jun 27 |
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
|
Jun 27 |
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
|
Jun 27 |
AbbVie buys bowel disease drug developer Celsius for $250M
|
Jun 27 |
AbbVie Acquires Celsius Therapeutics
|
Jun 27 |
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
|
Jun 27 |
Introducing Allē Payment Plans, Powered by Cherry
|
Jun 27 |
AbbVie expands its IBD prospects with $250M Celsius deal
|
Jun 27 |
Genmab, AbbVie win FDA nod for relapsed follicular lymphoma therapy
|